2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points

As we step into 2026, let’s look back at how neurotech unfolded over the past year. In 2025, neurotechnology broadened and sped up across multiple fronts. BCIs, brain-targeted delivery, neurodiagnostics, organoids, and neuro-focused AI all saw more activity moving from concept work into larger studies, bigger datasets, and concrete development plans, with sizable Series A-D rounds backing specific bets on CNS biology…

This article is for paid subscribers of BiopharmaTrend Pro membership.